Download presentation
1
Precancers and Skin Cancers
Adam O. Goldstein, MD, MPH Associate Professor Family Medicine University of North Carolina at Chapel Hill
2
Actinic Keratoses premalignant skin lesions = “keratinocytic intraepidermal neoplasia” chronic sun, radiation or polycyclic aromatic hydrocarbons Skin Type I-II organ transplant
3
Actinic Keratosis
4
Actinic Keratoses Distribution: Sunexposed, esp. dorsa hands/forearms
Description: papules,plaques with scale and erythema, occasional crust or cutaneous horn Sandpapery feel
5
Actinic Keratoses epidermal atypia abnormal maturation
6
Actinic Keratoses 60% predisposed >40 have at least 1 AK
6-10% lifetime >> invasive SCC >10 AK - 14% an SCC w/n 5 yrs 60-97% of SCC from AK ~ 40% of met SCC>> AK ^ aggressive immsupp
7
Actinic Keratoses lip lesions: actinic cheilitis/leukoplakia
white plaques-mucosa persistent scaling lesions on the lip ^ aggressive behavior tobacco/sun
8
Differential Diagnosis
squamous cell carcinoma: more indurated, thicker, recurrence of AK after treatment
9
Differential Diagnosis
seborrheic keratosis: hyperpigmented,more stuck on appearing
10
Differential Diagnosis
nummular eczema: coin-shaped scaling lesions; responds to emollients/topical corticosteroids
11
AK Treatment PREVENTION Screen for skin cancers Broad-brimmed hats
sun protective clothing sunscreens avoidance of sunlight ed s/sx skin cancer avoidance of tobacco low fat diet?
12
AK Treatment 5-fluorouracil cream or solution Diclofenac Sodium-3% gel
Cryosurgery(liquid nitrogen) 5-fluorouracil cream or solution Diclofenac Sodium-3% gel Imiquimod 2 x week/ 16 weeks
13
AK Treatment Excision Electrocautery Curettage Carbon dioxide laser
14
AK Treatment Photodynamic therapy Retinoids-topical/oral
Chemical peels Photodynamic therapy Retinoids-topical/oral Investigational-dimericine
15
TREATMENT Liquid Nitrogen-Advantages cure rates of 98.8% common
minimal patient ed multiple/thicker lesions quick recovery
16
TREATMENT Liquid Nitrogen-Disadvantages storage pain
pigment alteration training
17
5-Fluorouracil Cure 50-80% Blocks methylation reaction of deoxyuridylic acid to thymidilic acid DNA (and RNA) synthesis
18
Diclonfenac Sodium 3% Topical Gel
mechanism of action unknown NSAID inhibition of cyclo-oxygenase >>>PGE-2 90 days BID--overall 33-47% clearance vs 10-19% vehicle avoid ASA triad hypersensitivity
19
Photodynamic therapy (Pariser DM - J Am Acad Dermatol -2003)
20
Salasche SJ et al Am Acad Dermatol 2002;47:571-7.
Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: An open-label trial. Significant irritation Rest periods required Evolving protocols Expensive Effective Salasche SJ et al Am Acad Dermatol 2002;47:571-7.
21
Skin Cancer Statistics
>1 million cases/yr >50% of all new cancers 1 in 5 Americans will develop skin cancer
22
Types of Skin Cancers Basal Cell Carcinoma - 80%
Squamous Cell Carcinoma - 16% Melanoma - 4%
23
BCC /SCC Most common skin cancers Most important risk factors
sun exposure family history skin type Incidence of these cancers increase with age, probably related to cumulative sun exposure
24
Basal Cell Carcinoma the most common skin cancer
90% appear on face, ears, head
25
Main Types Basal Cell Carcinomas
Nodular BCCs - most common type Sclerosing BCCs (morpheaform) Superficial BCCs
26
Pattern of Nodular BCC raised pearly white, smooth translucent surface with telangiectasias
27
Pattern of Nodular BCCs
may ulcerate leaving a small bloody crust may be pigmented
28
Pattern of Sclerosing BCCs
ivory or colorless flat or atrophic indurated may resemble scars are easily overlooked
29
Pattern of Sclerosing BCCs
ivory or colorless flat or atrophic indurated may resemble scars are easily overlooked
30
Pattern of Superficial BCCs and SCC in situ
red or pink scaling plaques occasionally with shallow erosions or crusts differentiation between these two similar lesions usually requires a biopsy
31
Pigmented BCCs may look like melanoma increased brown or black pigment
seen more commonly in dark-skinned individuals
32
Differential Diagnosis of Nodular BCC
Intradermal nevus Sebaceous hyperplasia Fibrous papule of the face trichoepithelioma
33
Differentiating Intradermal Nevus from Nodular BCC
Stable size Soft No crusting or ulceration May have telangiectasias
34
Differentiating Intradermal Nevus from Nodular BCC
Stable size Soft No crusting or ulceration May have telangiectasias
35
Sebaceous Hyperplasia from Nodular BCC
yellow coloration stable size umbilication without ulceration is hard to see after injecting anesthesia
36
Diagnosis of Basal Cell Carcinomas
Shave biopsy nodular thick superficial types Punch biopsy morpheaform flat superficial types
37
Treatment options for Basal Cell Carcinomas
C + D after a shave biopsy Cryotherapy with thermocouple if you have experience Excision with 3- 5 mm margins Superficial trunk/ext: imiquimod qd x 12 wks Mohs for recurrent BCC and areas of cosmetic importance
38
Mohs micrographic surgery
removal of tumor by scalpel in sequential horizontal layers. each tissue sample is frozen, stained, and microscopically examined repeated until all the margins are clear treatment of choice for BCCs with poorly defined margins especially those on the nose or eyelids
39
Recurrence rates after Tx of BCCs
C + D 10% Cryotherapy 10% Excision 2 - 5% Imiquimod ??? Mohs <1%
40
Factors that increase recurrence rates
sclerosing vs others larger size of BCC margins experience of the surgeon
41
Sclerosing BCC is most dangerous
tend to be deeply invasive often not diagnosed until they have caused extensive damage invade muscle, nerve, and bone nodular BCC can also invade deeply
42
Bowen’s disease - features
SCC in situ Mainly sun exposed areas Slightly elevated red scaly plaque with well-demarcated borders
43
Bowen’s disease - features
May resemble psoriasis, superficial BCC, chronic eczema, SK Curable using C & D, cryo, 5-FU, imiquimod, excision
44
Keratoacanthoma Appear suddenly, grow rapidly
Central crater with keratin plug May grow to 2cm in size May resolve spontaneously May look like SCC
45
Keratoacanthoma C and D elliptical excision 5-FU topically tid
5-FU intralesional injection
46
Location of SCCs Same distribution as bccs.
Especially on the lips, ears, and scalp Initially grow by direct extension Metastasize to local lymph nodes and then to distant sites
47
SCCs with an increased risk of metastasis
larger, advanced lesions SCC on mucous membranes (in the oral cavity, on the lips) BCCs rarely metastasize
48
SCC more aggressive (local & mets)
Size >2 cm SCC in a scar Patient is immunosuppressed Poorly differentiated There is perineural invasion
49
Importance of early diagnosis of BCC and SCC
especially in facial cancers the nose is the single most frequent site of BCC reconstruction is difficult extension into underlying bone and cartilage may occur
50
The differential diagnosis of superficial BCC and SCC in situ
Actinic keratosis, nummular eczema Nummular eczema can usually be distinguished by its coin-like shape, transient nature, and itchiness Biopsy any thickened and crusting actinic keratosis to rule out BCC or SCC
51
Treatment options for SCC
C + D after a shave biopsy cryotherapy with thermocouple if you have experience excision with 5 mm margin Mohs for recurrent SCC and areas of cosmetic importance
52
Erythroplasia of Queyrat
SCC in situ on the penis Usually under the foreskin of the uncircumcised penis May occur on the vulva 5-FU, imiquimod or mohs
53
Indications for Referral for Mohs Surgery
54
Indications for Referral for Mohs Surgery
Recurrent tumors, sclerosing BCC Primary tumors in locations with high tumor-recurrence rates Nasolabial fold,temple, periauricular area, periocular area, scalp, nasal alae, center face Preservation of normal tissue is vital (for cosmetic and functional reasons) Nose, eyelids, lips, fingers, ears, penis
55
When to consider referral
Aggressive and recurrent skin cancers A large skin cancer lesion A lesion located in a sensitive area (cosmetic or functional) When treatment or diagnosis of the lesion is beyond the scope of one’s skills If mohs surgery is the treatment of choice
56
Melanoma Risk Factors Family history Personal history Atypical Nevi
Blistering Sunburns Type 1 skin
57
History of a changing lesion
58
Melanoma Statistics Fastest rising incidence rates
Most common cancer in 25-9 y/o 2nd only to breast CA in 30-4 y/o women
59
Melanoma Facts 87,900 new cancers 7400 deaths in 2003 due to melanoma
34,300 in situ 53,600 invasive 4% increase from 2001 7400 deaths in 2003 due to melanoma
60
Melanoma
61
Melanoma-Early detection
Total treatment costs by stage Stage I 5.5% Stage II 5.5% Stage III 34% Stage IV 55%
62
MNEMONIC FOR MALIGNANT MELANOMA RECOGNITION
A- ASYMMETRY B- BORDER IRREGULARITY C- VARIATION IN COLOR D- DIAMETER> .6CM E- ELEVATION ABOVE SKIN SURFACE
63
Melanoma with regression
64
Melanoma
65
Acral lentiginous Melanoma
66
Lentigo Maligna Melanoma
67
Venous Lake
68
Blue Nevus
69
Seborrheic Keratosis
70
Pyogenic Granuloma
71
Look everywhere
72
Melanoma Management Excisional “biopsy” 1-2 mm margins
Dermatopathologist consultation
73
Breslow’s Measurement
Depth of granular cell layer to deepest malignant cell Strongest correlation with prognosis
74
Melanoma Managment Sentinel lymph node biopsy
1mm or greater depth, regression, >Level III or IV Interferon Vaccine clinical trials
75
Melanoma Management Full skin exam Family screening Follow up
Education
76
Take home points Prevent skin cancers by risk factor reduction
Early detection of pre-cancers and skin cancers can prevent morbidity and mortality Use the appropriate biopsy technique for diagnosing skin cancers Treat or refer based on your skills
77
Online References Derm Online Atlas is at Derm Image Bank is at medstat.med.utah.edu/kw/derm/ Basal Cell Carcinoma is at emedicine.com/derm/topic47.htm
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.